DRAFT - February 7, 2024 

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) 

Centers for Disease Control and Prevention 

Atlanta, Georgia 30329 

February 28-29, 2024 

Wednesday, February 28, 2024 

8:00 Welcome & Introductions 

8:30 COVID-19 Vaccines 

Introduction 

COVID-19-associated hospitalizations among adults - COVID-NET 

COVID-19 vaccination coverage update 

COVID-19 vaccine effectiveness 

Economic analysis of an additional dose of COVID-19 vaccine 

Evidence to Recommendations or Work Group Considerations 

Next steps for the COVID-19 vaccine program 

Dr. Melinda Wharton (ACIP Executive Secretary, CDC) 

Dr. Matt Daley (ACIP, WG Chair) 

Dr. Christopher Taylor (CDC/NCIRD) 

Dr. Kevin Chatham-Stephens (CDC/NCIRD) 

Dr. Ruth Link-Gelles (CDC/NCIRD) 

Dr. Lisa Prosser (University of Michigan) 

Dr. Megan Wallace (CDC/NCIRD) 

Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD) 

10:50 Break 

11:10 Chikungunya Vaccines 

Introduction 

Vaccine use among pregnant and breastfeeding women 

Review of proposed policy options for chikungunya vaccine use 

among U.S. adults traveling abroad 

Review of proposed policy options for chikungunya vaccine use 

among laboratory workers 

Dr. Wilbur Chen (ACIP, WG Chair) 

Dr. Susan Hills (CDC/NCEZID), 

Dr. Dana Meaney-Delman (CDC/NCBDDD) 

Dr. Susan Hills (CDC/NCEZID) 

Dr. Susan Hills (CDC/NCEZID) 

12:25 Break 

1:25 DT Vaccine 

Guidance to use Td vaccine for those instances when receipt of the

pertussis component is contraindicated 

Dr. Michelle Hughes (CDC/NCIRD) 

Dr. Jeanne Santoli (CDC/NCIRD) 

1:35 Public Comment 

1:55 VOTES 

COVID-19 Vaccines 

Chikungunya Vaccines 

VFC VOTES 

Diphtheria, Tetanus, and Pertussis 

Dr. Megan Wallace (CDC/NCIRD) 

Dr. Susan Hills (CDC/NCEZID) 

Dr. Jeanne Santoli (CDC/NCIRD) 

2:25 Break 

2:40 Influenza Vaccines 

Introduction 

Interim U.S. Influenza Vaccine Effectiveness Estimates 

LAIV updates 

Dr. Jamie Loehr (ACIP, WG Chair) 

TBD 

Dr. C. Buddy Creech (Vanderbilt University Medical 

Center) 

4:25 Break 

4:40 Polio Vaccines 

Work Group deliberations on potential use of nOPV2 as an outbreak 

control measure in the US 

Clinical considerations for children who received fractional dose 

inactivated polio vaccine (fIPV) in other countries 

Dr. Sarah Kidd (CDC/NCIRD) 

Dr. Sarah Kidd (CDC/NCIRD) 

5:30 Adjourn 
DRAFT - February 7, 2024 

Thursday, February 29, 2024 

8:00 Welcome & Introductions 

8:10 Agency Updates 

8:30 Respiratory syncytial virus (RSV) Vaccines Adults 

Introduction 

Age-stratified rates of RSV-associated hospitalization among adults 

Risk-stratified rates of RSV-associated hospitalization among adults 

Implementation update: older adult RSV vaccination 

Post-marketing safety surveillance of older adult RSV vaccination 

Older adult RSV vaccination: benefits and risks discussion 

Manufacturer presentation: Moderna safety & efficacy in adults aged 

≥60 years

Work group interpretations and discussion 

11:30 Meningococcal Vaccines 

Introduction 

GSK Pentavalent MenABCWY vaccine: Term of Reference 

Revising the Adolescent Meningococcal Vaccine Schedule: Term of 

Reference and Considerations 

12:20 Break 

1:00 Pneumococcal Vaccines 

Introduction 

Current epidemiology of invasive pneumococcal disease and 

pneumococcal vaccine coverage in adults 

Preliminary findings of the Pneumococcal pNeumonia Epidemiology, 

Urine serotyping, and Mental Outcomes (PNEUMO) US study 

Phase 2/3 clinical trial data of PCV21 

Post-licensure PCV20 safety data 

PCV21 Policy Questions and Preliminary WG interpretations of EtR 

3:00 Break 

3:10 Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, 

Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, 

and Hepatitis B vaccine (Vaxelis®) 

Introduction and terms of reference 

Background on Hib disease and vaccination among American 

Indian/Alaska Native Populations 

Immunogenicity of Hib PRP-OMP vaccines in American Indian and 

Alaska Native infants 

Work group considerations 

4:30 Adjourn 

Dr. Melinda Wharton (ACIP Executive Secretary, CDC) 

Dr. Camille Kotton (ACIP, WG Chair) 

Dr. Fiona Havers (CDC/NCIRD) 

Dr. Rebecca Woodruff (CDC/NCCDPHP) 

Dr. Carla Black (CDC/NCIRD) 

TBD (CDC/NCEZID) 

Dr. Michael Melgar (CDC/NCIRD) 

TBD (Moderna) 

Dr. Amadea Britton (CDC/NCIRD) 

Dr. Jamie Loehr (ACIP, WG Chair) 

Dr. Sarah Schillie (CDC/NCIRD) 

Dr. Sarah Schillie (CDC/NCIRD) 

TBD (ACIP, WG Chair) 

Mr. Ryan Gierke (CDC/NCIRD) 

Dr. Wesley Self (Vanderbilt University Medical Center) 

(TBD) Merck 

Dr. Pedro Moro (CDC/NCEZID) and Dr. Richard Forshee 

(CMS) 

Dr. Miwako Kobayashi (CDC/NCIRD) 

Dr. Jamie Loehr (ACIP, WG Chair) 

Dr. Jennifer Collins (CDC/NCIRD) 

Dr. Laura Hammitt (Johns Hopkins Bloomberg School of 

Public Health - Center for Indigenous Health) 

Dr. Jennifer Collins (CDC/NCIRD) 
DRAFT - February 7, 2024 

Acronyms 

CDC Centers for Disease Control and Prevention 

CMS Centers for Medicare and Medicaid Services 

COVID-19 Coronavirus disease 2019 

EtR Evidence to Recommendations Framework 

FDA Food and Drug Administration 

GRADE Grading of Recommendations Assessment, Development and Evaluation 

HRSA Health Resources and Services Administration 

IHS Indian Health Service 

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention 

NCIRD National Center for Immunization & Respiratory Diseases 

NCEZID National Center for Emerging and Zoonotic Diseases 

NIAID National Institute of Allergy and Infectious Diseases 

OIDP Office of Infectious Disease and HIV/AIDS Policy 

SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 

WG Work Group 

WHO World Health Organization 

VE Vaccine Effectiveness